Coronary disease & ACSTrial design
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
- randomized trial with a 2 × 2 factorial design
- double-blind
Study context
- Population
- Patients with atherosclerotic cardiovascular disease (ASCVD) receiving low-dose aspirin
- Planned comparison
- enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care
- Primary endpoint
- Aspirin randomization: composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia; AIR randomization: additionally other forms of cardiovascular death
- Follow-up
- Median planned 2 years
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- Enrolment was completed on 28 January 2026
Original publication
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial. Eur Heart J Cardiovasc Pharmacother. Published 23 September 2026. doi:10.1093/ehjcvp/pvag071
Summarised from the published abstract; every number is checked against it